TriLink BioTechnologies is a leading contract development and manufacturing organization (CDMO) specializing in nucleic acid synthesis. We offer a comprehensive range of services, including the production of nucleic acids, nucleoside triphosphates (NTPs), and mRNA capping analogs, with expertise in scaling up mRNA, oligonucleotide, and plasmid production for therapeutic, vaccine, diagnostic, and biopharmaceutical applications.
A notable innovation from TriLink is our proprietary CleanCap® mRNA co-transcriptional capping technology, which streamlines mRNA manufacturing by eliminating additional enzymatic steps, achieving over 95% capping efficiency and enhancing yields compared to traditional methods.
We provide a range of manufacturing-grade products, from discovery-grade (research use only) to full Good Manufacturing Practice (GMP) grade, supporting clients from initial research phases through clinical trials. Our facilities in San Diego include a 32,000-square-foot cGMP-grade facility, demonstrating our commitment to advancing mRNA-based therapeutics and vaccines as they progress into later-stage clinical trials.
For more information about TriLink, visit www.trilinkbiotech.com.
